VimalKumarDerebailMDMPH FASN

Nephrology • Chapel Hill, NC

Glomerular Disease

Associate Professor of Medicine University of North Carolina at Chapel Hill School of Medicine

Join to view full profile

Dr. Derebail is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Derebail's full profile

Already have an account?

Office
7024 Burnett Womack Campus
# 7155
Chapel Hill, NC 27599
Phone+1 919-966-2561

Fax+1 919-966-4251

Education & Training

University of North Carolina HospitalsFellowship, Research Fellow in Nephrology, 2009 - 2011
University of North Carolina at Chapel Hill, Gillings School of Global Public HealthMPH, Epidemiology, 2007 - 2010
University of North Carolina HospitalsFellowship, Nephrology, 2006 - 2009
University of North Carolina HospitalsResidency, Internal Medicine, 2002 - 2005
Medical College of Georgia at Augusta UniversityClass of 2002, MD
Duke UniversityBS, Biology / Religion, 1993 - 1997

Certifications & Licensure

NC State Medical License 2002 - 2025
SC State Medical License 2021 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Nephrology

Clinical Trials

Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients Start of enrollment: 2011 Aug 01
Completed
Phase 4
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis Start of enrollment: 2014 Mar 01
Completed
Phase 2
Lipid Lowering Agents to Limit Lipid Oxidation and Activation of Clotting System in Nephrotic Syndrome Start of enrollment: 2012 May 01
Completed
Phase 1
Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease Start of enrollment: 2014 May 01
Completed
Phase 3
Pharmacokinetics of Apixaban in Nephrotic Syndrome Start of enrollment: 2017 Apr 30
Completed
Phase 1
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation Start of enrollment: 2016 Dec 01
Completed
Phase 4
A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis Start of enrollment: 2017 Mar 15
Completed
Phase 3
Kidney Function in Sickle Cell Anemia Start of enrollment: 2017 Nov 17
Active, not recruiting
Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN) Start of enrollment: 2017 Oct 06
Completed
Phase 2
Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS) Start of enrollment: 2018 Apr 17
Active, not recruiting
Phase 3
Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in GPA and MPA Start of enrollment: 2018 Oct 15
Terminated
Phase 2
ADPKD Alterations in Hepatic Transporter Function Start of enrollment: 2018 Sep 17
Completed
Tailoring Maintenance Therapy to Cluster of Differentiation 5 Positive (CD5+) Regulatory B Cell Recovery in ANCA Vasculitis Start of enrollment: 2019 Jun 28
Suspended
Not Applicable
Belimumab With Rituximab for Primary Membranous Nephropathy Start of enrollment: 2020 Mar 06
Active, not recruiting
Phase 2
A Study With Imlifidase in Anti-GBM Disease Start of enrollment: 2022 Dec 22
Recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

2 citations
Emerging Therapies and Advances in Sickle Cell Disease with a Focus on Renal Manifestations.
Mofiyin Obadina, Sam Wilson, Vimal K Derebail, Jane Little
Kidney360. 2023-07-01
1 citations
Pregnancy History and Kidney Disease Progression Among Women Enrolled in Cure Glomerulonephropathy.
Monica L Reynolds, Andrea L Oliverio, Jarcy Zee, Elizabeth M Hendren, Michelle M O'Shaughnessy
Kidney International Reports. 2023-04-01
139 citations
Association of sickle cell trait with chronic kidney disease and albuminuria in African Americans.
Rakhi P. Naik, Vimal K. Derebail, Morgan E. Grams, Nora Franceschini, Paul L. Auer
JAMA. 2014-11-26

Journal Articles

Effect of Renin‐Angiotensin‐Aldosterone System Blocking Agents on Progression of Glomerulopathy in Sickle Cell Disease
Vimal K Derebail, Kenneth I Ataga, British Journal of Haematology
DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS
Howard Trachtman, Peter Nelson, Abanti Chaudhuri, Jai Radhakrishnan, Olga Zhdanova, Debbie S Gipson, Tarak Srivastava, Kenneth Lieberman, Vimal Kumar Derebail, Jonatha..., Journal of the American Society of Nephrology

Abstracts/Posters

The Effect of Crizanlizumab Plus Standard of Care (SoC) Versus Soc Alone on Renal Function in Patients with Sickle Cell Disease and Chronic Kidney Disease: A Randomize...
Vimal K. Derebail, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Opioid Analgesics Are Associated with Albuminuria in Adult Patients with Sickle Cell Anemia
Vimal K. Derebail, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Manifestations of Reduced Kidney Function Occur at a Higher Estimated Glomerular Filtration Rate in Sickle Cell Anemia
Vimal K. Derebail, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Manifestations of Reduced Kidney Function Occur at a Higher Estimated Glomerular Filtration Rate in Sickle Cell Anemia
Vimal K. Derebail, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Association of Sickle Cell Trait with Measures of Cognitive Function and Dementia in African Americans
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Rapid Decline in Kidney Function in Sickle Cell Disease
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Sickle Cell Trait Is Not Risk Factor for Kidney Disease: Study Contradicts Earlier FindingsSeptember 14th, 2011
Sickle Cell Trait in African-American Dialysis Patients Affects Dosing of Anemia DrugsFebruary 10th, 2016